Radiolabeled HER2-directed exosomes exhibit improved cell targeting and specificity

Nanomedicine (Lond). 2021 Mar;16(7):553-567. doi: 10.2217/nnm-2020-0408. Epub 2021 Mar 17.

Abstract

Aim: Here, we established a reliable strategy for generation and characterization of targeted radiolabeled exosomes for the detection of HER2-positive cells quantitatively. Materials & methods: Targeted exosomes (T-exos) were radiolabeled by two different radiotracers, [99mTc]Tc-HMPAO or [111In]In-oxine. The labeling efficiency and stability were assessed using exosome exclusive spin columns. HER2-positive and -negative cells were treated with [111In]In-oxine-exosomes after 3 and 24 h. Results: [111In]In-oxine labeling did not change the binding ability and general features of the exosomes. With [111In]In-oxine, 70% labeling efficiency and 78% radiochemical stability over 24 h were achieved. [111In]In-oxine-T-exos showed greater uptake by HER2-positive cells compared with untargeted exosomes. Conclusion: [111In]In-oxine-T-exos could potentially be used as an effective imaging tool for HER2 expression.

Keywords: DARPin; HER2; breast cancer; imaging; radiotracer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Exosomes*
  • Radiopharmaceuticals
  • Receptor, ErbB-2

Substances

  • Radiopharmaceuticals
  • Receptor, ErbB-2